{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:42:56Z","timestamp":1782891776861,"version":"3.54.5"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"The Swedish Cancer Society","award":["CAN 2013\/701"],"award-info":[{"award-number":["CAN 2013\/701"]}]},{"DOI":"10.13039\/100016669","name":"Sj\u00f6berg Foundation","doi-asserted-by":"publisher","award":["2020-01-07-08"],"award-info":[{"award-number":["2020-01-07-08"]}],"id":[{"id":"10.13039\/100016669","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ume\u00e5 University Hospital","award":["RV-492791"],"award-info":[{"award-number":["RV-492791"]}]},{"name":"Ume\u00e5 University Hospital","award":["RV-764931"],"award-info":[{"award-number":["RV-764931"]}]},{"name":"Ume\u00e5 University Hospital","award":["RV-866041"],"award-info":[{"award-number":["RV-866041"]}]},{"DOI":"10.13039\/501100004886","name":"Cancer Research Foundation in Northern Sweden","doi-asserted-by":"publisher","award":["LP 18-2185"],"award-info":[{"award-number":["LP 18-2185"]}],"id":[{"id":"10.13039\/501100004886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004886","name":"Cancer Research Foundation in Northern Sweden","doi-asserted-by":"publisher","award":["LP 20-2249"],"award-info":[{"award-number":["LP 20-2249"]}],"id":[{"id":"10.13039\/501100004886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Glioblastoma is the most aggressive and malignant brain tumor, characterized by a high degree of heterogeneity, invasiveness, and resistance to treatment. Patients with glioblastoma have a very poor prognosis despite multimodal interventions. In this study, we investigated how 18F-fluorothymidine (18F-FLT) PET combined with contrast-enhanced MRI and blood metabolomics can contribute to evaluate prognosis and treatment response for patients with glioblastoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients, scheduled for surgery due to suspected high-grade glioma were included in this clinical study and underwent four 18F-FLT-PET\/MRI examinations prior to surgery and during standard treatment. Blood samples were collected and analyzed by metabolomics. Patients were grouped according to survival as long-time survivors (&amp;gt;3 years) and short-time survivors (&amp;lt;500 days).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Both 2 and 6 weeks into treatment, short-time survivors displayed a significantly larger tumor volume than long-time survivors. When comparing MRI findings during treatment, long-time survivors displayed a substantial tumor decrease, whereas the short-time survivors showed minor or no effect. Regarding 18F-FLT-PET the results were not as unambiguous. Furthermore, there was a clear and significant separation in the metabolomic pattern in blood between the survival groups and across treatment time points.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>MRI measures of tumor volume and growth during treatment appear to be prognostic clinical factors that affect outcome. Metabolomic patterns in blood differ significantly between the defined survival groups and may serve as support for an early forecast of prognosis. We also observe a clear separation in metabolite levels between different time points during treatment, which likely reflects treatment effects.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdaf034","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T13:13:38Z","timestamp":1739020418000},"source":"Crossref","is-referenced-by-count":1,"title":["Characterizing long- and short-survival glioblastoma patients with FLT-PET\/MRI and metabolomics"],"prefix":"10.1093","volume":"7","author":[{"given":"Jan","family":"Axelsson","sequence":"first","affiliation":[{"name":"Department of Diagnostics and Interventions, Radiation Physics, Ume\u00e5 University , Ume\u00e5 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9347-5790","authenticated-orcid":false,"given":"Benny","family":"Bj\u00f6rkblom","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Ume\u00e5 University , Ume\u00e5 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Asklund","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Interventions, Oncology, Ume\u00e5 University , Ume\u00e5 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Brandel","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Interventions, Diagnostic Radiology, Ume\u00e5 University , Ume\u00e5 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svante","family":"Larhed","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Interventions, Oncology, Ume\u00e5 University , Ume\u00e5 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela M","family":"Ringmar","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Interventions, Oncology, Ume\u00e5 University , Ume\u00e5 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Hedman","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Molecular Imaging and Medical Physics, Uppsala University , Uppsala ,","place":["Sweden"]},{"name":"Department of Diagnostics and Interventions, Radiation Physics, Ume\u00e5 University , Ume\u00e5 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Riklund","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Interventions, Diagnostic Radiology, Ume\u00e5 University , Ume\u00e5 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rickard L","family":"Sj\u00f6berg","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Neurosciences, Ume\u00e5 University , Ume\u00e5 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4328-8561","authenticated-orcid":false,"given":"Maria","family":"Sandstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Interventions, Oncology, Ume\u00e5 University , Ume\u00e5 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"issue":"7","key":"2025050308211481600_CIT0001","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: A review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA."},{"issue":"3","key":"2025050308211481600_CIT0002","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/0284186X.2019.1571278","article-title":"Improved treatment of glioblastoma - changes in survival over two decades at a single regional Centre","volume":"58","author":"Eriksson","year":"2019","journal-title":"Acta Oncol."},{"issue":"8","key":"2025050308211481600_CIT0003","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol"},{"issue":"10","key":"2025050308211481600_CIT0004","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"23","key":"2025050308211481600_CIT0005","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA."},{"key":"2025050308211481600_CIT0006","volume-title":"National Guidlines for tumours in the brain, spinal cord and its membranes","year":"2023"},{"issue":"2","key":"2025050308211481600_CIT0007","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/0284186X.2017.1337926","article-title":"U-CAN: A prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden","volume":"57","author":"Glimelius","year":"2018","journal-title":"Acta Oncol."},{"issue":"9","key":"2025050308211481600_CIT0008","first-page":"1431","article-title":"Understanding the standardized uptake value, its methods, and implications for usage","volume":"45","author":"Thie","year":"2004","journal-title":"J Nucl Med."},{"issue":"9","key":"2025050308211481600_CIT0009","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/neuonc\/noac042","article-title":"Distinct metabolic hallmarks of WHO classified adult glioma subtypes","volume":"24","author":"Bj\u00f6rkblom","year":"2022","journal-title":"Neuro Oncol"},{"key":"2025050308211481600_CIT0010","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.4c01799","article-title":"OPLS-based multiclass classification and data-driven inter-class relationship discovery","author":"Forsgren","year":"2025","journal-title":"J Chem Inf Model."},{"issue":"10","key":"2025050308211481600_CIT0011","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med."},{"issue":"3","key":"2025050308211481600_CIT0012","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"issue":"1","key":"2025050308211481600_CIT0013","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer."},{"issue":"1","key":"2025050308211481600_CIT0014","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s12149-016-1129-0","article-title":"Intratumoral heterogeneity of (18)F-FLT uptake predicts proliferation and survival in patients with newly diagnosed gliomas","volume":"31","author":"Mitamura","year":"2017","journal-title":"Ann Nucl Med."},{"key":"2025050308211481600_CIT0015","doi-asserted-by":"crossref","first-page":"109663","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother Oncol."},{"issue":"13","key":"2025050308211481600_CIT0016","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","article-title":"MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients","volume":"26","author":"Brandes","year":"2008","journal-title":"J Clin Oncol."},{"issue":"1","key":"2025050308211481600_CIT0017","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00330-016-4346-y","article-title":"Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation","volume":"27","author":"Yoon","year":"2017","journal-title":"Eur Radiol."},{"issue":"9","key":"2025050308211481600_CIT0018","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1021\/bi00223a030","article-title":"Metabolic origin of urinary 3-hydroxy dicarboxylic acids","volume":"30","author":"Tserng","year":"1991","journal-title":"Biochemistry."},{"issue":"21","key":"2025050308211481600_CIT0019","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.3390\/jcm10214855","article-title":"Biochemical markers for the diagnosis of mitochondrial fatty acid oxidation diseases","volume":"10","author":"Ruiz-Sala","year":"2021","journal-title":"J Clin Med"},{"issue":"22","key":"2025050308211481600_CIT0020","doi-asserted-by":"crossref","first-page":"13933","DOI":"10.3390\/ijms232213933","article-title":"Mitochondrial fatty acid beta-oxidation disorders: From disease to lipidomic studies-a critical review","volume":"23","author":"Guerra","year":"2022","journal-title":"Int J Mol Sci ."},{"issue":"1","key":"2025050308211481600_CIT0021","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12929-023-00956-w","article-title":"Role of mitochondrial alterations in human cancer progression and cancer immunity","volume":"30","author":"Wang","year":"2023","journal-title":"J Biomed Sci."},{"issue":"Pt 2","key":"2025050308211481600_CIT0022","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/bj20021528","article-title":"second messenger or modulator of membrane structure and dynamics","volume":"369","author":"van Blitterswijk","year":"2003","journal-title":"Biochem J."},{"issue":"11","key":"2025050308211481600_CIT0023","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.freeradbiomed.2006.01.035","article-title":"Sphingolipid signaling and redox regulation","volume":"40","author":"Won","year":"2006","journal-title":"Free Radic Biol Med."},{"key":"2025050308211481600_CIT0024","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fimmu.2019.00090","article-title":"The role of glycosphingolipids in immune cell functions","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol."},{"issue":"10","key":"2025050308211481600_CIT0025","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2217\/fon.10.116","article-title":"Sphingolipids and cancer: Ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance","volume":"6","author":"Ponnusamy","year":"2010","journal-title":"Future Oncol."},{"issue":"3","key":"2025050308211481600_CIT0026","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10863-005-6567-7","article-title":"Mitochondrial ceramide and the induction of apoptosis","volume":"37","author":"Siskind","year":"2005","journal-title":"J Bioenerg Biomembr."},{"key":"2025050308211481600_CIT0027","doi-asserted-by":"crossref","first-page":"816301","DOI":"10.3389\/fcell.2021.816301","article-title":"Role of ceramides in the molecular pathogenesis and potential therapeutic strategies of cardiometabolic diseases: what we know so far","volume":"9","author":"Shalaby","year":"2021","journal-title":"Front Cell Dev Biol."},{"issue":"10","key":"2025050308211481600_CIT0028","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.bbamcr.2016.01.023","article-title":"Carnitine transport and fatty acid oxidation","volume":"1863","author":"Longo","year":"2016","journal-title":"Biochim Biophys Acta."},{"key":"2025050308211481600_CIT0029","doi-asserted-by":"crossref","first-page":"110119","DOI":"10.1016\/j.cellsig.2021.110119","article-title":"Role of ceramide\/sphingomyelin (SM) balance regulated through \u201cSM cycle\u201d in cancer","volume":"87","author":"Taniguchi","year":"2021","journal-title":"Cell Signal."},{"issue":"1","key":"2025050308211481600_CIT0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/cancers11010088","article-title":"The opposing contribution of SMS1 and SMS2 to glioma progression and their value in the therapeutic response to 2OHOA","volume":"11","author":"Fernandez-Garcia","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2025050308211481600_CIT0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-94-007-6331-9_1","article-title":"Sphingomyelin and its role in cellular signaling","volume":"991","author":"Chakraborty","year":"2013","journal-title":"Adv Exp Med Biol."},{"issue":"6","key":"2025050308211481600_CIT0032","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s12276-023-01018-9","article-title":"Functional roles of sphingolipids in immunity and their implication in disease","volume":"55","author":"Lee","year":"2023","journal-title":"Exp Mol Med."},{"key":"2025050308211481600_CIT0033","doi-asserted-by":"crossref","first-page":"900082","DOI":"10.3389\/fonc.2022.900082","article-title":"Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide","volume":"12","author":"Lodi","year":"2022","journal-title":"Front Oncol."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf034\/61812085\/vdaf034.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf034\/61812085\/vdaf034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf034\/61812085\/vdaf034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T12:21:28Z","timestamp":1746274888000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf034\/8005709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf034","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"vdaf034"}}